Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
48 studies found for:    Belimumab
Show Display Options
Rank Status Study
1 Terminated Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant
Condition: Desensitization Before Kidney Transplant
Intervention: Drug: Belimumab
2 Unknown  A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia
Condition: Symptomatic Waldenstroms Macroglobulinaemia
Intervention: Drug: Belimumab
3 Terminated
Has Results
Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Belimumab 100 mg SC
4 Recruiting Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy
Condition: Systemic Lupus Erythematosus
Intervention: Biological: belimumab
5 Completed
Has Results
A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Belimumab plus Early Vaccination;   Biological: Belimumab plus Late Vaccination
6 Active, not recruiting Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Condition: Systemic Sclerosis
Intervention: Drug: Belimumab
7 Recruiting Belimumab (BENLYSTA®) Pregnancy Registry
Condition: Systemic Lupus Erythematosus
Intervention: Drug: belimumab
8 Completed Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome
Condition: Sjögren's Syndrome
Intervention: Drug: Belimumab
9 Recruiting Belimumab Impacting Transplant Eligibility
Condition: Renal Transplant Rejection
Interventions: Drug: belimumab;   Drug: Bortezomib;   Drug: Rituximab;   Drug: Plasmapheresis
10 Recruiting Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry
Condition: Systemic Lupus Erythematosus
Interventions: Biological: BENLYSTA;   Other: SLE treatment
11 Completed
Has Results
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 10 mg/kg
12 Active, not recruiting Belimumab in Remission of VASculitis
Condition: Vasculitis
Interventions: Biological: Placebo;   Biological: Belimumab 10 mg/kg;   Drug: Azathioprine
13 Completed Efficacy and Safety of Belimumab in Primary Sjögren's Syndrome
Condition: Sjögren's Syndrome
Intervention: Drug: LimphoStat-B
14 Completed A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy Subjects
Condition: Systemic Lupus Erythematosus
Intervention: Drug: Belimumab 200 mg/mL
15 Recruiting Belimumab in Myositis
Condition: Myositis
Interventions: Drug: Belimumab;   Drug: Placebo
16 Completed
Has Results
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo;   Drug: Belimumab 1 mg/kg;   Drug: Belimumab 10 mg/kg
17 Recruiting Belimumab Assessment of Safety in SLE
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Other: Standard therapy
18 Completed A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo;   Biological: Belimumab 200 mg SC;   Drug: Standard therapy
19 Recruiting Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis
Condition: Lupus Nephritis
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy
20 Recruiting Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)
Condition: Systemic Lupus Erythematosus
Interventions: Biological: Placebo plus standard therapy;   Biological: Belimumab 10 mg/kg plus standard therapy;   Drug: Standard therapy

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.